関: idiopathic hypersomnia

WordNet

(of diseases) arising from an unknown cause; "idiopathic epilepsy"

PrepTutorEJDIC

特発性疾患の(病気の原因があいまいな,また不明な場合)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 特発性過眠症 idiopathic hypersomnia
2. 過度な日中の眠気を有する患者へのアプローチ approach to the patient with excessive daytime sleepiness
3. クライネ・レビン症候群（反復性過眠症） kleine levin syndrome recurrent hypersomnia
4. 眠気の定量化 quantifying sleepiness
5. 睡眠障害の分類 classification of sleep disorders

English Journal

Polysomnographic study of nocturnal sleep in idiopathic hypersomnia without long sleep time.

Pizza F1, Ferri R, Poli F, Vandi S, Cosentino FI, Plazzi G.Author information 1Department of Neurological Sciences, University of Bologna/IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy.AbstractWe investigated nocturnal sleep abnormalities in 19 patients with idiopathic hypersomnia without long sleep time (IH) in comparison with two age- and sex- matched control groups of 13 normal subjects (C) and of 17 patients with narcolepsy with cataplexy (NC), the latter considered as the extreme of excessive daytime sleepiness (EDS). Sleep macro- and micro- (i.e. cyclic alternating pattern, CAP) structure as well as quantitative analysis of EEG, of periodic leg movements during sleep (PLMS), and of muscle tone during REM sleep were compared across groups. IH and NC patients slept more than C subjects, but IH showed the highest levels of sleep fragmentation (e.g. awakenings), associated with a CAP rate higher than NC during lighter sleep stages and lower than C during slow wave sleep respectively, and with the highest relative amount of A3 and the lowest of A1 subtypes. IH showed a delta power in between C and NC groups, whereas muscle tone and PLMS had normal characteristics. A peculiar profile of microstructural sleep abnormalities may contribute to sleep fragmentation and, possibly, EDS in IH.
Journal of sleep research.J Sleep Res.2013 Apr;22(2):185-96. doi: 10.1111/j.1365-2869.2012.01061.x. Epub 2012 Oct 15.
We investigated nocturnal sleep abnormalities in 19 patients with idiopathic hypersomnia without long sleep time (IH) in comparison with two age- and sex- matched control groups of 13 normal subjects (C) and of 17 patients with narcolepsy with cataplexy (NC), the latter considered as the extreme of
PMID 23061443

Sleep stage sequence analysis of sleep onset REM periods in the hypersomnias.

Drakatos P1, Suri A, Higgins SE, Ebrahim IO, Muza RT, Kosky CA, Williams AJ, Leschziner GD.Author information 1Sleep Disorders Centre, Guy’s and St Thomas’ Hospital NHS Foundation Trust, London, UK.AbstractBACKGROUND: The Multiple Sleep Latency Test (MSLT) remains an important diagnostic tool in the diagnosis of hypersomnias. However, a positive MSLT may be found in other sleep disorders, such as behaviourally induced inadequate sleep syndrome (BIISS). It has been demonstrated that in sleep onset rapid eye movement (SOREM) periods in BIISS, REM sleep tends to arise from stage 2 sleep (non-REM (NREM) 2), rather than stage 1 sleep (NREM1), as in narcolepsy.
Journal of neurology, neurosurgery, and psychiatry.J Neurol Neurosurg Psychiatry.2013 Feb;84(2):223-7. doi: 10.1136/jnnp-2012-303578. Epub 2012 Oct 20.
BACKGROUND: The Multiple Sleep Latency Test (MSLT) remains an important diagnostic tool in the diagnosis of hypersomnias. However, a positive MSLT may be found in other sleep disorders, such as behaviourally induced inadequate sleep syndrome (BIISS). It has been demonstrated that in sleep onset rapi
PMID 23085931

Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review.

Nittur N1, Konofal E, Dauvilliers Y, Franco P, Leu-Semenescu S, Cock VC, Inocente CO, Bayard S, Scholtz S, Lecendreux M, Arnulf I.Author information 1National Reference Centre for Narcolepsy and Idiopathic Hypersomnia, France.AbstractOBJECTIVE: Mazindol is a tricyclic, anorectic, non-amphetamine stimulant used in narcolepsy and obesity since 1970. This study aimed to evaluate the long-term benefit/risk ratio in drug-resistant hypersomniacs and cataplexy sufferers.
Sleep medicine.Sleep Med.2013 Jan;14(1):30-6. doi: 10.1016/j.sleep.2012.07.008. Epub 2012 Oct 1.
OBJECTIVE: Mazindol is a tricyclic, anorectic, non-amphetamine stimulant used in narcolepsy and obesity since 1970. This study aimed to evaluate the long-term benefit/risk ratio in drug-resistant hypersomniacs and cataplexy sufferers.METHODS: By retrospective analysis of the patients' files in the h
PMID 23036267